Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1196 participants.
Also called NCT07763405
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,196 participants
- Registry
-
NCT07763405
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07763405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Lumbrokinase
- Intervention (Drug)
- Lumbrokinase Placebo
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Collaborator
- The First Affiliated Hospital of Nanchang University
Record details
- Record id
cardio:ct-nct07763405- Content hash
dc67123519a0ade8c41c66a1d9bdd26707a13fd54fe594c7ffbd09fc1ec168a8